Tg Therapeutics (TGTX) Debt to Equity (2019 - 2025)
Tg Therapeutics (TGTX) has 7 years of Debt to Equity data on record, last reported at $0.38 in Q4 2025.
- For Q4 2025, Debt to Equity fell 65.51% year-over-year to $0.38; the TTM value through Dec 2025 reached $0.38, down 65.51%, while the annual FY2025 figure was $0.38, 65.51% down from the prior year.
- Debt to Equity reached $0.38 in Q4 2025 per TGTX's latest filing, down from $0.4 in the prior quarter.
- Across five years, Debt to Equity topped out at $3.52 in Q1 2023 and bottomed at $0.05 in Q3 2021.
- Average Debt to Equity over 5 years is $0.84, with a median of $0.61 recorded in 2023.
- Peak YoY movement for Debt to Equity: surged 1278.44% in 2022, then crashed 82.01% in 2024.
- A 5-year view of Debt to Equity shows it stood at $0.29 in 2021, then soared by 324.93% to $1.21 in 2022, then plummeted by 48.63% to $0.62 in 2023, then skyrocketed by 76.22% to $1.1 in 2024, then crashed by 65.51% to $0.38 in 2025.
- Per Business Quant database, its latest 3 readings for Debt to Equity were $0.38 in Q4 2025, $0.4 in Q3 2025, and $0.89 in Q2 2025.